SEARCH

SEARCH BY CITATION

References

  • 1
    Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev 2009; Oct 21. [Epub ahead of print] PMID: 19845871
  • 2
    Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.0. The Cochrane Collaboration; updated February 2008. Available at www.cochrane-handbook.org. Accessed May 26, 2009.
  • 3
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; Jul 22. [Epub ahead of print] PMID: 19631508
  • 4
    Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. HEPATOLOGY 2010; 51: 121-129.
  • 5
    Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. HEPATOLOGY 2008; 48: 119-128.
  • 6
    Harrison SA, Brunt EM, Fecht WJ, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis (NASH): a randomized prospective trial. HEPATOLOGY 2009; 49: 80-86.
  • 7
    Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, et al. The effect of one year of intensive lifestyle intervention on hepatic steatosis [Abstract]. HEPATOLOGY 2008; 48( Suppl.): 812A.
  • 8
    Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 639-644.
  • 9
    Bonekamp S, Barone BB, Clark J, Stewart KJ. The effects of an exercise training intervention on hepatic steatosis [Abstract]. HEPATOLOGY 2008; 48( Suppl.): 806A.
  • 10
    Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, et al. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. HEPATOLOGY 2009; 50: 1105-1112.
  • 11
    St. George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with non-alcoholic fatty liver. HEPATOLOGY 2009; 50: 68-76.
  • 12
    Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009; 136: 1552-1560.
  • 13
    Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107-1115.
  • 14
    Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307.
  • 15
    Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-1184.
  • 16
    Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-110.
  • 17
    Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M, et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 28: 200-208.
  • 18
    Gastaldelli A, Harrison SA, Belfort R, Hardies LJ, Balas B, Schenker S, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of NASH patients. HEPATOLOGY 2009; 50: 1087-1093.
  • 19
    Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, et al. The effects of discontinuing pioglitazone in patients with non-alcoholic steatohepatitis. HEPATOLOGY 2007; 46: 424-429.
  • 20
    Argo CK, Iezzoni JC, Al-Osaimi AM, Caldwell SH. Thiazolidinediones in NASH: sustained benefit after drug discontinuation? J Clin Gastroenterol 2009; 43: 565-568.
  • 21
    Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the FLIRT-2 extension trial. HEPATOLOGY 2010; 51: 445-453.
  • 22
    Chalasani N, Sanyal AJ, Kowdley KV, Robuck PR, Hoofnagle J, Kleiner DE, et al. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp Clin Trials 2009; 30: 88-96.
  • 23
    Sanyal AJ. A randomized controlled trial of pioglitazone or vitamin E for nonalcoholic steatohepatitis (PIVENS). HEPATOLOGY 2009; 50: 1A.
  • 24
    Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-544.
  • 25
    Haukeland JW, Konopski Z, Beate Eggesbø H, von Volkmann HL, Raschpichler G, Bjøro K, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scandinavian Journal of Gastroenterology 2009; 44: 853-860.
  • 26
    Shields WW, Thompson KE, Grice GA, et al. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Ther Adv Gastroenterology 2009; 2: 157-163.
  • 27
    Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082-1090.
    Direct Link:
  • 28
    Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 2009; 46: 113-118.
  • 29
    Torres DM, Jones FJ, Williams CD, Harrison S. The effect of 48 weeks of rosiglitazone alone versus combination rosiglitazone and metformin (Avandamet) versus combination rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis (NASH): a open-label prospective randomised clinical trial [Abstract]. HEPATOLOGY 2009; 50: 390A.
  • 30
    Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, et al. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010; 22: 18-23.
  • 31
    Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53: 2169-2176.
  • 32
    Fabbrini E, Conte C, Magkos F. Methods for assessing intrahepatic fat content and steatosis. Curr Opin Clin Nutr Metab Care 2009; 12: 474-481.
  • 33
    Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liv Dis 2008; 40: 194-199.
  • 34
    Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 2008; 14: 6395-6400.
  • 35
    Cussons AJ, Watts GF, Mori TA, Stuckey BGA. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 2009; 94: 3842-3848.
  • 36
    Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384.
  • 37
    De Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a metaanalysis. Pharmacotherapy 2004; 24: 584-591.
  • 38
    Browning JD. Statins and hepatic steatosis: perspectives from the Dallas Heart Study. HEPATOLOGY 2006; 44: 466-471.
  • 39
    Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97: 77C-81C.
  • 40
    Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 2009; 43: 990-994.
  • 41
    Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-883.
  • 42
    Ekstedt M, Franzen LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007; 47: 135-141.
  • 43
    Merat S, Malekzadeh R, Sohrabi MR, Sotoudeh M, Rakhshani N, Sohrabpour AA, et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003; 38: 414-418.
  • 44
    Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for the treatment of non-alcoholic steatohepatitis: results of a randomized trial. HEPATOLOGY 2004; 39: 770-778.
  • 45
    Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in non-alcoholic steatohepatitis. Clin Gastroenterol Hepatol 2006; 4: 1537-1543.
  • 46
    Ratziu V, De Ledinghen V, Oberti F, et al. A multicentric, double-blind, randomised-controlled trial (RCT) of high dose ursodeoxycholic acid in patients with nonalcoholic steatohepatitis (NASH). J Hepatol 2009; 50( 4 Suppl): S21.
  • 47
    Santos VN, Lanzoni VP, Szejnfeld D, Shigueoka D, Parise ER. A randomized double-blind study of the short-time treatment of obese patients with non-alcoholic fatty liver disease with ursodeoxycholic acid. Braz J Med Biol Res 2003; 36: 723-729.
  • 48
    Mendez-Sanchez N, Gonzalez V, Chavez-Tapia N, Ramos MH, Uribe M. Weight reduction and ursodeoxycholic acid in subjects with non-alcoholic fatty liver disease: a double-blind, placebo-controlled trial. Ann Hepatol 2004; 3: 108-112.
  • 49
    Ersoz G, Gunsar F, Karasu Z, Akay S, Batur Y, Akarca US. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk J Gastroenterol 2005; 16: 124-128.
  • 50
    Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. HEPATOLOGY 2003; 38: 413-419.
  • 51
    Rui M, Wang C, Fang J, de Sá SV, Simplicio FI, de Mello ES, et al. The clinical comparison of reduced glutathione and DaiNingPlan in the treatment of non-alcoholic steatohepatitis. Chinese General Practice 2001; 4: 269-270.
  • 52
    Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with non-alcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-2490.
    Direct Link:
  • 53
    Abdelmalek MF, Sanderson SO, Angulo P, Soldevila-Pico C, Liu C, Peter J, et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. HEPATOLOGY 2009; 50: 1818-1826.
  • 54
    Pamuk GE, Sonsuz A. N-acetylcysteine in the treatment of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2003; 18: 1220-1221.
  • 55
    Miglio F, Rovati LC, Santoro A, Senikar I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis: a double-blind, randomized, parallel group, placebo-controlled prospective clinical study. Arzneimittelforschung 2000; 50: 722-727.
  • 56
    Vilar Gomez E, Rodriguez DE, Miranda A, Arus Soler E, Llanio Navarro R, Calzadilla Bertot L, et al. Clinical trial: Viusid(R) in combination with diet and exercise in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2009; 30: 999-1009.
  • 57
    Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142: 37-46.
  • 58
    Buranawui W, Thung-u-thaisri P, Pramoolsinsap C, et al. Pentoxifylline for treatment of non-alcoholic fatty liver disease (NAFLD): a randomized, placebo-controlled study [Abstract s2161]. Gastroenterology 2006; A330.
  • 59
    Lee YM, Sutedja D, Wai CT, Dan YY, Aung MO, Zhou L, et al. A randomized controlled pilot study of pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2008; 2: 196-201.
  • 60
    Rinella ME, Koppe S, Brunt EM, et al. Pentoxifylline improves ALT and histology in patients with NASH: a double-blind placebo controlled trial. Gastroenterology 2009; 136:[ Supplement DDW].
  • 61
    Georgescu EF, Ionescu R, Georgescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15: 942-954.
  • 62
    Després JP, Ross R, Boka G, Alméras N, Lemieux I. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009; 29: 416-423.
  • 63
    Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, et al. L-carnitine supplementation to diet: a new tool intreatment of nonalcoholic steatohepatitis: a randomizedand controlled clinical trial. Am J Gastroenterol 2010; doi:10.1038/ajg.2009.719.
  • 64
    Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on non-alcoholic fatty liver disease (NAFLD): systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 1396-1402.
  • 65
    Mattar GS, Velcu LM, Rabinovitz M, Demetris AJ, Krasinskas AM, Barinas-Mitchell E, et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005; 242: 610-620.
  • 66
    Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. A prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009; 137: 532-540.
  • 67
    Luyckx Fh, Desaive C, Thiry A, Dewé W, Scheen AJ, Gielen JE, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998; 22: 222-226.
  • 68
    Arase Y, Suzuki F, Ikeda K, Kumada H, Tsuji H, Kobayashi T. Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastroenterol 2009; 44: 1064-1070.
  • 69
    Wadden TA, Smith West D, Delahanty LM, Jakicic J, Rejeski J, Williamson D, et al. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity 2006; 14: 737-752.
  • 70
    Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371-379.